TransEnterix, Inc. (NYSEAMERICAN:TRXC) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 36,349,828 shares, a drop of 11.5% from the October 15th total of 41,056,924 shares. Currently, 21.3% of the shares of the company are sold short. Based on an average daily trading volume, of 7,223,997 shares, the short-interest ratio is currently 5.0 days.
Several brokerages recently issued reports on TRXC. Zacks Investment Research raised shares of TransEnterix from a “sell” rating to a “hold” rating in a report on Friday. LADENBURG THALM/SH SH raised shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a report on Friday. Finally, BTIG Research reissued a “hold” rating on shares of TransEnterix in a report on Tuesday, September 25th.
In related news, Director William N. Starling, Jr. sold 1,700,000 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $6.40, for a total transaction of $10,880,000.00. Following the completion of the transaction, the director now owns 66,987 shares of the company’s stock, valued at $428,716.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Joseph P. Slattery sold 64,651 shares of the firm’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $5.74, for a total transaction of $371,096.74. Following the transaction, the chief financial officer now directly owns 11,951 shares of the company’s stock, valued at approximately $68,598.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,909,224 shares of company stock valued at $18,271,761.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRXC. BlackRock Inc. increased its holdings in TransEnterix by 467.9% in the second quarter. BlackRock Inc. now owns 9,870,565 shares of the medical instruments supplier’s stock valued at $43,036,000 after buying an additional 8,132,481 shares in the last quarter. Global X Management Co LLC purchased a new position in TransEnterix in the second quarter valued at $11,212,000. Millennium Management LLC increased its holdings in TransEnterix by 787.5% in the first quarter. Millennium Management LLC now owns 1,895,115 shares of the medical instruments supplier’s stock valued at $3,222,000 after buying an additional 1,681,583 shares in the last quarter. UBS Group AG grew its position in shares of TransEnterix by 1,658.3% in the first quarter. UBS Group AG now owns 906,280 shares of the medical instruments supplier’s stock valued at $1,541,000 after purchasing an additional 854,737 shares during the period. Finally, Eagle Asset Management Inc. grew its position in shares of TransEnterix by 152.9% in the second quarter. Eagle Asset Management Inc. now owns 791,165 shares of the medical instruments supplier’s stock valued at $3,449,000 after purchasing an additional 478,286 shares during the period.
TRXC opened at $3.22 on Friday. TransEnterix has a fifty-two week low of $1.27 and a fifty-two week high of $6.98.
TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Thursday, November 8th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $5.40 million during the quarter, compared to analysts’ expectations of $5.40 million. The firm’s revenue for the quarter was up 2850.8% compared to the same quarter last year.
ILLEGAL ACTIVITY NOTICE: “Short Interest in TransEnterix, Inc. (TRXC) Drops By 11.5%” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/11/short-interest-in-transenterix-inc-trxc-drops-by-11-5.html.
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.